Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVericel Corp Ord

Vericel Corp Ord

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
54.62 USD 2.84 ( 5.48%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1612191
Market Cap
2033.93M
P/E
82.75

Momentum Score

…

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
50.76
Low
54.64
High
52 Week Price Range
28.95
Low
49.32
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
51.78
Dividend Yield
-
Revenue TTM
306.30M
Revenue Per Share
6.04
Gross Profit TTM
228.38M
Debt / Equity
0.28
ROE
7.16%
Net Debt
-1.83M
ROCE
4.31%
Diluted EPS TTM
0.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 17.38M 10.51M -2.37M -15.99M -7.58M
Net income 16.52M 10.36M -3.18M -16.71M -7.47M
Selling general administrative 166.99M 142.79M 117.04M 106.90M 97.59M
Gross profit 205.60M 172.11M 135.58M 109.79M 106.03M
Reconciled depreciation 11.54M 5.50M 4.52M 3.98M 2.96M
Ebit 18.93M 11.12M -1.77M -17.06M -7.85M
Ebitda 30.29M 16.63M 2.86M -15.62M -7.58M
Depreciation and amortization 11.36M 5.50M 4.63M 1.44M 0.28M
Non operating income net other - - - 1.44M 0.28M
Operating income 11.04M 4.52M -6.46M -17.06M -7.85M
Other operating expenses 265.21M 232.71M 203.98M 181.42M 164.04M
Interest expense 1.56M 0.61M 0.60M 0.37M 0.00M
Tax provision 0.86M 0.15M 0.41M 0.72M -0.11M
Interest income 7.01M 6.41M 3.96M 1.34M 0.22M
Net interest income 6.38M 5.80M 3.29M 0.97M 0.22M
Income tax expense 0.86M 0.15M 0.81M 0.72M -0.11M
Total revenue 276.26M 237.22M 197.52M 164.37M 156.18M
Total operating expenses 194.56M 167.59M 142.04M 126.85M 113.88M
Cost of revenue 70.66M 65.12M 61.94M 54.58M 50.16M
Total other income expense net 6.33M 5.99M 4.10M 1.07M 0.27M
Net income from continuing ops 16.52M 10.36M -10.25M -16.71M -7.47M
Net income applicable to common shares - - - -16.71M -7.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 487.97M 432.72M 353.66M 273.00M 243.71M
Intangible assets 5.62M 6.25M 6.88M 7.50M -
Other current assets 7.74M 17.82M 6.85M 4.80M 4.25M
Total liab 133.33M 140.75M 127.70M 80.73M 73.24M
Total stockholder equity 354.64M 291.97M 225.95M 192.27M 170.46M
Other current liab 19.24M 17.18M 17.21M 16.23M 0.04M
Common stock 730.66M 684.78M 629.23M 593.25M 553.90M
Capital stock 730.66M 684.78M 629.23M 593.25M 553.90M
Retained earnings -376.30M -392.81M -403.18M -400.00M -383.29M
Other liab - - - - 0.04M
Other assets - - 0.00M 1.30M 0.53M
Cash 100.09M 74.52M 86.87M 51.07M 68.33M
Total current liabilities 49.15M 50.29M 45.75M 37.46M 26.05M
Current deferred revenue - - - - 14.04M
Net debt -1.83M 24.33M 1.28M -3.50M -18.23M
Short term debt 14.09M 9.26M 6.19M 4.30M 2.95M
Short long term debt total 98.27M 98.85M 88.14M 47.57M 50.10M
Other stockholder equity 0.28M - - 592.27M 177.93M
Property plant equipment - - - 57.37M 59.03M
Total current assets 247.44M 212.78M 205.63M 186.87M 158.46M
Long term investments 61.40M 39.88M 25.28M 19.96M 25.69M
Net tangible assets - - - 184.77M 170.46M
Short term investments 37.41M 41.69M 40.47M 68.47M 35.07M
Net receivables 84.63M 61.38M 58.36M 46.54M 37.44M
Inventory 17.56M 17.37M 13.09M 15.99M 13.38M
Accounts payable 15.83M 23.85M 22.35M 16.93M 9.02M
Accumulated other comprehensive income 0.28M 0.00M -0.10M -0.98M -0.15M
Common stock total equity - - - 593.25M 553.90M
Retained earnings total equity - - - -400.00M -383.29M
Non currrent assets other 0.34M 0.56M 0.77M 1.30M 0.53M
Non current assets total 240.53M 219.94M 148.03M 86.14M 85.24M
Capital lease obligations 96.37M 98.85M 88.04M 47.61M 50.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -16.77M -79.03M -16.77M -36.21M 4.41M
Change to liabilities - - - 3.58M 4.24M
Total cashflows from investing activities -43.94M -79.03M -3.13M -36.21M -3.50M
Net borrowings - - - -1.08M -
Total cash from financing activities 7.07M 19.05M 3.62M 1.04M 9.17M
Change to operating activities - - - -0.94M -0.69M
Net income 16.52M 10.36M -3.18M -16.71M -7.47M
Change in cash 15.04M -1.82M 35.80M -17.47M 34.71M
Begin period cash flow 85.05M 86.87M 51.07M 68.54M 33.83M
End period cash flow 100.09M 85.05M 86.87M 51.07M 68.54M
Total cash from operating activities 51.91M 58.16M 35.31M 17.69M 29.04M
Issuance of capital stock 13.93M 24.52M 5.23M 3.65M 11.18M
Depreciation 11.36M 5.50M 4.63M 3.98M 2.96M
Other cashflows from investing activities -27.16M -63.97M -27.51M - -
Change to inventory -1.23M -4.29M 2.90M -2.60M -4.03M
Change to account receivables -23.26M -3.02M -11.82M -9.10M -2.93M
Sale purchase of stock - - - 3.65M 11.18M
Other cashflows from financing activities -6.86M -5.46M -2.38M -2.61M -2.01M
Change to netincome - - - 37.20M 34.33M
Capital expenditures 27.16M 63.97M 27.51M 7.60M 7.92M
Change receivables - - - -9.10M -2.93M
Cash flows other operating - - - 1.14M 0.98M
Cash and cash equivalents changes - - - -17.47M 34.71M
Change in working capital -21.36M -0.45M -3.96M -11.21M -6.15M
Stock based compensation 38.77M 36.49M 32.33M 37.18M 34.32M
Other non cash items 6.62M 6.25M 5.50M 3.72M 4.43M
Free cash flow 24.75M -5.81M 7.80M 10.09M 21.12M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VCEL
Vericel Corp Ord		 2.84
5.48%		 54.62 82.75 58.14 6.64 5.48 6.39 50.67
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Vericel Corp Ord

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

25 Blue Sky Drive, Burlington, MA, United States, 01803

617 588 5555

https://www.vcel.com

398

Name Title Year Born
Mr. Dominick C. Colangelo Esq. CEO, Pres & Director 1964
Mr. Joseph Anthony Mara Jr. CFO & Treasurer 1976
Mr. Michael Halpin Chief Operating Officer 1961
Mr. Sean C. Flynn Sr. VP, Gen. Counsel & Sec. 1974
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. Chief Medical Officer 1962
Mr. Jonathan Siegal Principal Accounting Officer, VP & Corp. Controller NA
Mr. Eric Burns Exec. Director of Financial Planning and Analysis & Investor Relations NA
Mr. Patrick J. Fowler Sr. VP of Corp. Devel. & Strategy NA
Ms. Heidi Hassen VP of HR NA
Mr. Roland DeAngelis Sr. VP of Commercial Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.49%

  • Communication Services

    +0.10%

  • Consumer Cyclical

    +0.03%

  • Consumer Defensive

    +0.87%

  • Energy

    +0.64%

  • Financial Services

    +0.26%

  • Healthcare

    +2.59%

  • Industrials

    +0.89%

  • Real Estate

    +0.03%

  • Technology

    +0.88%

  • Utilities

    +0.81%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…